Verastem Inc (VSTM) — Trending Stock Buzzer

Xavier Trudeau
Juillet 17, 2017

According to the analysts, Verastem Inc (NASDAQ:VSTM) is expected to announce $-0.34/share EPS for the current quarter. The institutional investor owned 373,420 shares of the biopharmaceutical company's stock after selling 700 shares during the period.

Several other research firms have also recently issued reports on VSTM. Renaissance Technologies LLC boosted its stake in shares of Verastem by 13.6% in the fourth quarter. They now have a $1.50 price objective on the biopharmaceutical company's stock. The shares price has positioned 135.06% up over the past quarter while it has directed 238.02% toward a rising position throughout past six months.

Verastem Inc (NASDAQ:VSTM) now has a trailing P/E of -3.68 while its forward P/E according to Thomson Reuters is -2.84. Renaissance Technologies LLC now owns 1,022,200 shares of the biopharmaceutical company's stock worth $1,145,000 after buying an additional 122,600 shares during the last quarter. The company's market capitalization is $152.41 million.

Shares of Verastem Inc (NASDAQ:VSTM) now have an Average Brokerage Recommendation of 1.75, number of Recs in ABR is 4 while industry rank of the company by ABR is out of 265. Verastem Inc has a 12-month low of $1.05 and a 12-month high of $4.15.

Verastem (NASDAQ VSTM) traded down 9.71% during mid-day trading on Friday, reaching $3.72.

In the last reported quarter, Verastem Inc reported its Actual EPS (earnings per share) of $-0.35/share where most of the analysts working on this stock were estimating the EPS to be $-0.35/share. The company has its outstanding shares of 548.81 million. If you are reading this piece of content on another domain, it was stolen and republished in violation of worldwide trademark and copyright laws. Zacks Investment Research cut Verastem from a hold rating to a sell rating in a report on Tuesday, May 16th. Out of the analyst recommendations 1 rate Verastem Inc (NASDAQ:VSTM) stock a Buy, 2 rate the stock Outperform, 2 rate Hold, 0 rate Underperform and 0 recommend a Sell. Cantor Fitzgerald reiterated a "hold" rating and issued a $2.00 price target on shares of Verastem in a report on Thursday, May 11th. Oppenheimer Holdings, Inc. set a $6.00 price target on shares of Verastem and gave the company a "buy" rating in a report on Wednesday, May 10th. Finally, Jefferies Group LLC reiterated a "hold" rating and issued a $1.50 price target on shares of Verastem in a report on Wednesday, June 28th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock.

The Average Volume for 10 days is 4.54 Million for Verastem Inc (NASDAQ:VSTM).

In other Verastem news, Director Timothy J. Barberich bought 30,000 shares of the stock in a transaction on Monday, May 15th. The stock has a beta value of 2.12. Following the transaction, the director now owns 69,462 shares of the company's stock, valued at approximately $170,181.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The Company operates in the segment of developing drugs for the treatment of cancer.

Let's take an assessment at how Verastem, Inc.

D'autres rapports CampDesrEcrues

Discuter de cet article